pioglitazone + statin

**Pioglitazone + statin** is a combination drug regimen comprising pioglitazone, a thiazolidinedione that acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, and a statin, which is an inhibitor of hydroxymethylglutaryl-CoA reductase. Pioglitazone improves insulin sensitivity, modulates inflammation, and enhances adiponectin in patients with insulin resistance or metabolic syndrome. Statins, such as simvastatin or atorvastatin, lower LDL cholesterol, raise HDL cholesterol, and decrease cardiovascular events by reducing cholesterol synthesis in the liver. Several clinical studies demonstrate that combining pioglitazone with a statin exerts additive anti-inflammatory effects, as measured by biomarkers like C-reactive protein and matrix metalloproteinase-9, with complementary benefits on lipid and metabolic profiles in patients with cardiovascular risk factors, with or without diabetes[1][2][4].

Brand names

pioglitazone + statin

Other names

pioglitazone + statin